Long-term follow-up of children with high-risk neuroblastoma: The ENSG5 trial experience
| Autor: | Andrew D.J. Pearson, J. Imeson, Ian Lewis, C. Ross Pinkerton, Lucas Moreno, Sucheta Vaidya, David Machin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Melphalan
Ependymoma medicine.medical_specialty Pediatrics business.industry Induction chemotherapy Hematology medicine.disease law.invention Surgery Clinical trial Oncology Randomized controlled trial law Pediatrics Perinatology and Child Health Cohort Carcinoma Medicine business Adverse effect medicine.drug |
| Zdroj: | Pediatric Blood & Cancer. 60:1135-1140 |
| ISSN: | 1545-5009 |
| DOI: | 10.1002/pbc.24452 |
| Popis: | Background Therapy for high-risk neuroblastoma is intensive and multimodal, and significant long-term adverse effects have been described. The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial. Procedure The trial protocol included induction chemotherapy (randomized Standard OPEC/OJEC vs. Rapid COJEC), surgery of primary tumor and high-dose melphalan with stem cell rescue. Two hundred and sixty-two children were randomized, 69 survived >5 years, and 57 were analyzed. Data were obtained from the ENSG5 trial database and verified with questionnaires sent to participating centers. Results Median follow-up was 12.9 (6.916.5) years. No differences were found in late toxicities between treatment arms. Twenty-eight children (49.1%) developed hearing loss. Nine patients (15.8%) developed glomerular filtration rate |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text